What role does measuring medication compliance play in evaluating the efficacy of naltrexone?

Alcoholism: Clinical and Experimental Research

Volumn 31, Issue 4, 2007, Pages 596-603

  Baros, Alicia M ^a,b   Latham, Patricia K ^a   Moak, Darlene H ^a   Voronin, Konstantin ^a   Anton, Raymond F ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcoholism; Cognitive Behavioral Therapy; Medication Compliance; Naltrexone

Indexed keywords

NALOXONE; PLACEBO; RIBOFLAVIN;

ABSTINENCE; ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG MONITORING; FEMALE; FLUOROMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; MOTIVATIONAL ENHANCEMENT THERAPY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINALYSIS;

ADULT; ALCOHOLISM; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RIBOFLAVIN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 33947200411     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2007.00343.x     Document Type: Article

References (33)

1. Adams SG Jr., Howe JT (1993) Predicting medication compliance in a psychotic population. J Nerv Ment Dis 181:558-560.
2. Anton RF (1996) New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res 20:3A-9A.
3. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R (2005) Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 25:349-357.
4. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
5. Anton RF, Swift RM (2003) Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict 12 (suppl 1): S53-S68.
6. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, Group VANS (2003) Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6:566-573.
7. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3273-3277.
8. Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196-201.
9. Cramer JA, Scheyer RD, Mattson RH (1990) Compliance declines between clinic visits [see comment]. Arch Intern Med 150:1509-1510.
10. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195-203.
11. Del Boca FK, Kranzler HR, Brown J, Korner PF (1996) Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 20:1412-1417.
12. Fuller R, Roth H, Long S (1983) Compliance with disulfiram treatment of alcoholism. J Chronic Dis 36:161-170.
13. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al (1986) Disulfiram treatment of alcoholism. A veterans administration cooperative study. JAMA 256:1449-1455.
14. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study G (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293:1617-1625.
15. Haynes RB, Taylor DW, Sackett DL (1979) Compliance in Health Care. Johns Hopkins University Press, Baltimore.
16. Kadden RR, Carroll KM, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R (1994) Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. DHHS Publication No. 94-3724, vol. 3. NIAAA, Rockville, MD.
17. Kranzler HR (2000) Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 35:537-547.
18. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335-1341.
19. Mark TL, Kranzler HR, Song X (2003) Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71:219-228.
20. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001) Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25:537-547.
21. Melnikow J, Kiefe C (1994) Patient compliance and medical research: issues in methodology. J Gen Intern Med 9:96-105.
22. Miller WR, Zweben A, DiClemente CC, Rychtarik RG (1994) Motivational Enhancement Therapy Manual. DHHS Publication No. 94-3723, vol. 2. NIAAA, Rockville, MD.
23. Morris L, Schultz RM (1992) Patient compliance - an overview. J Clin Pharm Ther 17:283-295.
24. Nichol MB, Venturini F, Sung JC (1999) A critical evaluation of the methodology of the literature on medication compliance. Ann Pharmacother 33:531-540.
25. O'Brien CP, Volpicelli LA, Volpicelli JR (1996) Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 13:35-39.
26. Olivieri NF, Matsui D, Hermann C, Koren G (1991) Compliance assessed by the medication event monitoring system. Arch Dis Child 66:1399-1402.
27. O'Malley SS, Carroll KM (1996) Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res 20:17A-22A.
28. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP (1999) The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 16:163-167.
29. Pettinati HM, Volpicelli JR, Pierce JD Jr., O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19:71-83.
30. Pettinati HM, Weiss RD, Dundon W, Miller WR, Donovan D, Ernst DB, Rounsaville BJ (2005) A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 15:170-178.
31. Rohsenow DJ, Colby SM, Monti PM, Swift RM, Martin RA, Mueller TI, Gordon A, Eaton CA (2000) Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 24:1542-1549.
32. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544-552.
33. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-742.